UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063181
Receipt number R000072309
Scientific Title A nationwide cohort study on long-term outcomes of hemodiafiltration in incident dialysis patients: dose-response relationship of substitution volume
Date of disclosure of the study information 2026/10/05
Last modified on 2026/10/05 19:43:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A nationwide cohort study on long-term outcomes of hemodiafiltration in incident dialysis patients: dose-response relationship of substitution volume

Acronym

HDF volume and outcomes in incident dialysis

Scientific Title

A nationwide cohort study on long-term outcomes of hemodiafiltration in incident dialysis patients: dose-response relationship of substitution volume

Scientific Title:Acronym

HDF dose-response in incident dialysis

Region

Japan


Condition

Condition

End-stage kidney disease requiring dialysis initiation

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine whether hemodiafiltration (HDF), compared with hemodialysis (HD), reduces all-cause mortality in incident dialysis patients, and whether a dose-response relationship exists between HDF substitution volume (<40 L / 40-49 L / 50 L or more) and all-cause mortality.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

All-cause mortality during follow-up from the exposure assessment time

Key secondary outcomes

1) Cardiovascular mortality and infection-related mortality (cause-specific Cox models)
2) Dose-response relationship between HDF substitution volume and all-cause mortality (restricted cubic splines)
3) Risk differences and restricted mean survival time (RMST) differences at 3, 5 and 8 years


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who initiated maintenance dialysis between January 2015 and September 2023 at facilities participating in the JSDT Renal Data Registry (JRDR)

Key exclusion criteria

Age <18 years; history of PD or kidney transplantation before HD/HDF initiation; death, transplantation or loss to follow-up before the exposure assessment time; not thrice-weekly dialysis; session <4 h; blood flow <180 mL/min; excluded modalities (offline/push-pull HDF, AFBF, IHDF, home HD, etc.); combined HD/HDF or PD therapy

Target sample size

380000


Research contact person

Name of lead principal investigator

1st name Tomoyuki
Middle name
Last name Fujikura

Organization

Hamamatsu University School of Medicine

Division name

Internal Medicine 1

Zip code

431-3192

Address

1-20-1 Handayama, Chuo-ku, Hamamatsu city, Shizuoka

TEL

053-435-2261

Email

tfuji@hama-med.ac.jp


Public contact

Name of contact person

1st name Tomoyuki
Middle name
Last name Fujikura

Organization

Hamamatsu University School of Medicine

Division name

Internal Medicine 1

Zip code

431-3192

Address

1-20-1 Handayama, Chuo-ku, Hamamatsu city, Shizuoka

TEL

053-435-2261

Homepage URL


Email

tfuji@hama-med.ac.jp


Sponsor or person

Institute

Hamamatsu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee, Japanese Society for Dialysis Therapy

Address

2-38-21 Hongo, Bunkyo-ku, Tokyo

Tel

03-5800-0708

Email

office@jsdt.or.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

26-2

Org. issuing International ID_1

Medicine Ethics Committee of the Japanese Society for Dialysis Therapy

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

浜松医科大学(静岡県)


Other administrative information

Date of disclosure of the study information

2026 Year 10 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

380000

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2026 Year 08 Month 20 Day

Date of IRB

2026 Year 08 Month 20 Day

Anticipated trial start date

2026 Year 08 Month 20 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

A retrospective cohort study (as-treated analysis) using secondary data from the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR). Incident dialysis patients (January 2015 to September 2023) are classified into HD and HDF groups (substitution volume <40 L / 40-49 L / 50 L or more). Follow-up is up to approximately 9 years (administrative censoring at the end of 2024). All-cause mortality is analyzed by IPTW-weighted Cox models, with dose-response assessed using restricted cubic splines.


Management information

Registered date

2026 Year 10 Month 05 Day

Last modified on

2026 Year 10 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072309